Approval · Notice of Compliance 22244 · 2019
3TC: Notice of Compliance 22244
Issued June 5, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22244
- Date
- June 5, 2019
- Company
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to dosing recommendations for pediatric patients and safety updates
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| 3TC | Not yet assigned | — |
Medicinal ingredients
- LAMIVUDINE 150 MG per TAB
- LAMIVUDINE 300 MG per TAB
- LAMIVUDINE 10 MG per ML